References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2016-4-92-96

mrj-725

Research Article

ОБЗОРЫ

REVIEWS

О МЕСТЕ ПРЕПАРАТОВ ГИАЛУРОНОВОЙ КИСЛОТЫ У ПАЦИЕНТОВ С РАЗНЫМИ ФЕНОТИПАМИ ОСТЕОАРТРИТА КОЛЕННЫХ СУСТАВОВ

THE PLACE OF HYALURONIC ACID PREPARATIONS IN PATIENTS WITH DIFFERENT PHENOTYPES OF KNEE OSTEOARTHRITIS

Теплякова

О. В.

Teplyakova

O. V.

Контакты: Ольга Вячеславовна Теплякова; ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России, 620028, Екатеринбург, ул. Репина, 3

Contact: Olga Vyacheslavovna Teplyakova; Ural State Medical University, Ministry of Health of Russia, 3, Repin St., Yekaterinburg 620028

oteplyakova69@gmail.com

Уральский государственный медицинский университетРоссияUral State Medical UniversityRussian Federation

2016

16122016

1049296

2016

Теплякова О.В.

Teplyakova O.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/725

Обсуждается проблема фенотипирования остеоартрита (ОА) коленного сустава. Сделано предположение, что существующие противоречия между клиническими рекомендациями разных лет, как и недостаточная эффективность их практического использования, могут быть связаны с клиническими особенностями отдельных фенотипов ОА, что имеет большое значение для развития индивидуальных терапевтических подходов у таких пациентов. Рассмотрено место Hylan G-F 20 в алгоритме лечения ОА коленного сустава с учетом разных вариантов течения заболевания.

The paper discusses the problem of phenotyping of knee osteoarthritis (OA). It is assumed that that existing differences between clinical recommendations of different years, as the inadequate efficiency of their practical application, may be associated with the clinical features of individual OA phenotypes. It is of great importance in selecting individual therapeutic approaches in these patients. The place of Hylan G-F20 inthe treatment algorithm for knee OA is considered, by taking into account different types of the disease.

остеоартритколенный суставфенотипыгиалуроновая кислотаHylan G-F 20

osteoarthritisknee jointphenotypeshyaluronic acidHylan G-F 20

References1

Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008 Feb;16(2):137-62. doi:10.1016/j.joca.2007.12.013.

McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi:10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.

Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014 Jul;78(3): 184-7. doi:10.1016/j.maturitas.2014.04.015. Epub 2014 May 1.

Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74.

Hochberg M, Chevalier X, Henrotin Y, et al. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? Curr Med Res Opin. 2013 Mar;29(3):259-67. doi:10.1185/03007995.2012.753430. Epub 2013 Jan 31.

Zhang W, Doherty M, Peat G, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010 Mar;69(3):483-9. doi: 10.1136/ard.2009.113100. Epub 2009 Sep 17.

Wesseling J, Boers M, Viergever MA, et al. Cohort Profile: Cohort Hip and Cohort Knee (CHECK) study. Int J Epidemiol. 2016 Feb;45(1):36-44. doi:10.1093/ije/dyu177. Epub 2014 Aug 29.

Wesseling J, Bastick AN, ten Wolde S, et al. Identifying Trajectories of Pain Severity in Early Symptomatic Knee Osteoarthritis: A 5-year Followup of the Cohort Hip and Cohort Knee (CHECK) Study. J Rheumatol. 2015 Aug;42(8):1470-7. doi:10.3899/jrheum.141036. Epub 2015 Jul 1.

Bastick AN, Wesseling J, Damen J, et al. Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective cohort study (CHECK). Br J Gen Pract. 2016 Jan;66(642):e32-9. doi:10.3399/bjgp15X688129. Epub 2015 Dec 6.

Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Moreland LW, editors. Arthritis and Allied Conditions: A Textbook of Rheumatology. Baltimore: Lippincott, Williams Wilkins; 2005. P. 2199-226.

Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425.

Cruz-Almeida Y, King CD, Goodin BR, et al. Psychological profiles and pain characteristics of older adults with knee osteoarthritis. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1786-94.

Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a metaanalysis. JAMA. 2009 Jan 14;301(2):198-209. doi:10.1001/jama.2008.944.

Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2005 Apr;52(4):1264-73.

van Spil WE, Jansen NW, Bijlsma JW, et al. Clusters within a wide spectrum of biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals with very early symptomatic osteoarthritis. Osteoarthritis Cartilage. 2012 Jul;20(7): 745-54. doi:10.1016/j.joca.2012.04.004. Epub 2012 Apr 11.

Ayral X, Dougados M, Listrat V, et al. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol. 1996 Apr;23(4):698-706.

Felson DT. Identifying different osteoarthritis phenotypes through epidemiology. Osteoarthritis Cartilage. 2010 May;18(5): 601-4. doi:10.1016/j.joca.2010.01.007. Epub 2010 Feb 6.

Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi:10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.

Cutolo M, Berenbaum F, Hochberg M, et al. Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum. 2015 Jun;44(6):611-7. doi:10.1016/j.semarthrit.2014.12.003. Epub 2014 Dec 24.

Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi:10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.

Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005321.

Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015 Jan 6;162(1):46-54. doi:10.7326/M14-1231.

Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Apr;43(5):593-9. doi:10.1016/j.semarthrit.2013.10.002. Epub 2013 Oct 14.

Manna F, Dentini M, Desideri P, et al. Comparative chemical evaluation of two commercially available derivatives of hyaluronic acid (hylaform from rooster combs and restylane from streptococcus) used for soft tissue augmentation. J Eur Acad Dermatol Venereol. 1999 Nov;13(3):183-92.

Pena Ede L, Sala S, Rovira JC, et al. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. Pain. 2002 Oct;99(3):501-8.

Brown TJ, Laurent UB, Fraser JR. Turnover of hyaluronan in synovial joints: elimination of labeled hyaluronan from the knee joint of the rabbit. Exp Physiol. 1991 Jan;76(1):125-34.

Lindqvist U, Tolmachev V, Kairemo K, et al. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603-13.

Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylanbased viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012 Feb;100(2):457-62. doi:10.1002/jbm.b.31971. Epub 2011 Nov 21.

Henrotin Y, Raman R, Richette P, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum. 2015 Oct;45(2):140-9. doi:10.1016/j.semarthrit.2015.04.011. Epub 2015 Apr 30.

Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006 May;33(5): 946-50.

Chen CP, Hsu CC, Pei YC, et al. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. Exp Gerontol. 2014 Apr;52:30-5. doi:10.1016/j.exger.2014.01.016. Epub 2014 Jan 30.

Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml Hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010 Jan; 69(1):113-9. doi:10.1136/ard.2008.094623.

Raman R, Dutta A, Day N, et al. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee – a prospective randomized clinical trial. Knee. 2008 Aug;15(4):318-24. doi: 10.1016/j. knee.2008.02.012. Epub 2008 Apr 21.

Caborn D, Rush J, Lanzer W. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004 Feb;31(2):333-43.

Waddell DD, Joseph B. Delayed Total Knee Replacement with Hylan G-F 20. J Knee Surg. 2016 Feb;29(2):159-68. doi:10.1055/s-0034-1395281. Epub 2014 Oct 28.

Migliore A, Bizzi E, De Lucia O, et al. Differences among Branded Hyaluronic Acids in Italy, Part 1: Data from In Vitro and Animal Studies and Instructions for Use. Clin Med Insights Arthritis Musculoskelet Disord. 2016 May 25;9:89-101. doi:10.4137/CMAMD.S38857. eCollection 2016.

HTTP://www.accessdata.fda.gov/cdrh_docs/PDF/P940015S012a.pdf

Yoshida M, Sai S, Marumo K, et al. Expression analysis of three isoforms of hyaluronan synthase and hyaluronidase in the synovium of knees in osteoarthritis and rheumatoid arthritis by quantitative real-time reverse transcriptase polymerase chain reaction. Arthritis Res Ther. 2004;6(6):R514-20. Epub 2004 Sep 22.

The authors declare that there are no conflicts of interest present.